medications similar to semaglutide like and Tirzepatide are not just for diabetes and weight loss! Major clinical trials like PIONEER 6 and SUSTAIN 6 have shown that Semaglutide also significantly reduces the risk of Semaglutide GLP-1 vs. Ozempic vs.

A secondary outcome was change in body weight

The distribution map of SEMA in the central nervous system shows a greater presence in the septal nuclei compared to LIRA.19 In addition to reducing food intake, SEMA has proven effective in modulating food preferences,12 likely through dopaminergic activation of the ventral tegmental area and a reduction in endocannabinoid tone.19 The subsequent activation of the parabrachial nucleus and other neural circuits involved in the hedonic regulation of food intake may be specific to SEMA, potentially helping to explain its differences from LIRA.19 The mechanisms involved in the improvement of glycaemic control by LIRA 3 mg and SEMA 2.4 mg are related to their incretin and glucagonostatic effects inherent to GLP-1 receptor agonism,3 as well as to those derived from weight loss, reduction in fat mass, and their associated consequences.20 Effects on other comorbidities The SCALE programme shows that the apnoea-hypopnoea index reduces in cases of sleep apnoea syndrome when LIRA is used instead of a placebo (12.2 vs 6.1, p = 0.015).21 The contribution of weight loss to the effects of LIRA treatment in the SCALE programme varies

Nothing shared in this training, podcast, or any related content should be interpreted as medical advice, diagnosis, or treatment

quindi fondamentale che il percorso terapeutico venga svolto affidandosi a psicologi esperti in DCA che, affiancati da un team multidisciplinare di medici e nutrizionisti, possono supportare la persona attraverso il percorso di gestione prima, e guarigione poi

In the USA, dedicated resources, including strategies focused on diverse recruitment and retention and outreach efforts, are being implemented to include participants from ethnic and racial minorities, as well as those from different socioeconomic backgrounds, who are usually underrepresented in AD clinical trials [67]